サンプル依頼リスト カート
  • English
  • Korean
表紙：糖尿病性神経障害性疼痛の世界市場-2023年～2030年
市場調査レポート
商品コード
1345410

糖尿病性神経障害性疼痛の世界市場-2023年～2030年

Global Diabetic Neuropathic Pain Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
糖尿病性神経障害性疼痛の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

糖尿病性神経障害性疼痛の世界市場は、2022年に18億米ドルに達し、2023～2030年の予測期間中にCAGR 6.1％で成長し、2030年には28億米ドルに達すると予測されます。

糖尿病性神経障害に対する新規治療法の開拓は、世界の糖尿病性神経障害性疼痛市場の動向です。例えば、2023年7月27日、グジャラート州を拠点とする製薬会社Asprius Lifesciences社は、身体の末梢部分に神経障害が生じる糖尿病性神経障害に対する治療薬を開発したと発表しました。同社は、世界人口の2％以上が罹患している末梢神経障害の治療薬として有望なFixed-Dose Combination（FDC）の特許をすでに申請しているといいます。

糖尿病による神経損傷は糖尿病性神経障害につながり、血糖値がコントロールできない高血糖から生じる症状です。糖尿病性神経障害性疼痛は、この状態から生じる慢性疼痛です。この痛みは、灼熱感、不快感、しびれ、しびれ、撃つような痛み、刺すような痛みなどの症状を示します。糖尿病性神経障害性疼痛には、末梢神経障害、自律神経障害、近位神経障害、局所神経障害があります。糖尿病性神経障害性疼痛の治療法としては、鎮痛薬、抗うつ薬、抗けいれん薬などがあります。

さらに、薬剤の臨床試験の増加、末梢神経障害の有病率の増加、糖尿病性神経障害性疼痛の新規治療などが、予測期間中に市場を牽引すると予想される要因です。

ダイナミクス

糖尿病性神経障害性疼痛に対する潜在的治療法が市場成長を牽引すると期待される

2022年に発表された米国立生物工学情報センター（National Center for Biotechnology Information）の論文は、糖尿病性神経障害患者の神経血流を改善し、酸化ストレスを軽減し、遠位神経伝導を高める可能性のある強力な抗酸化物質としてのリポ酸の有効性に光を当てています。この強力な抗酸化物質は、痛みを伴う糖尿病性神経障害患者の症状を緩和し、QOLを改善することから、糖尿病性神経障害性疼痛の有望な治療法として提案されています。

さらに、リポ酸は重要な内因性抗酸化物質である還元型グルタチオンのレベルを上昇させ、血糖値の調節を助けることが示されています。臨床試験では、600mgのα-リポ酸が糖尿病性神経障害に伴う疼痛の管理に有効であることが判明しました。しかし、その有効性と安全性を確立するためには、さらなる研究が必要です。

したがって、リポ酸が市場に与える影響は、結局のところ、糖尿病性神経障害性疼痛に苦しむ人々のための実用的な治療法として、最近の進歩がうまく反映されるかどうかにかかっています。したがって、上記の要因により、予測期間中、市場は牽引役となることが期待されます。

糖尿病性神経障害性疼痛治療薬の臨床試験の増加が市場成長を促進する見込み

EPPIC-Net：Novaremed Painful Diabetic Peripheral Neuropathy ISA（EN21-01）は、有痛性糖尿病性末梢神経障害（PDPN）の症状緩和におけるNRD135Sの可能性を探ることを目的とした進行中の臨床試験です。二重盲検第Ⅱ相試験として、13週間にわたりNRD135Sの薬物動態／薬力学、安全性、忍容性、有効性を評価するようデザインされています。

現在開発中のNRD135Sは、PDPNの治療オプションとして期待される新規薬剤です。調査の目的は、糖尿病性神経障害の疼痛に対する安全性と有効性を評価するために、有効成分を含まないプラセボ錠とその効果を比較することです。

Novaremed Ltd.が実施する臨床試験は、米国と欧州の複数の場所で行われます。参加者は無作為にNRD135Sを投与される群とプラセボ錠を投与される群に振り分けられ、偏りのない結果が保証されます。安全性と有効性が確認されれば、NRD135SはPDPNに苦しむ人々に大きな影響を与える可能性があります。結果は2023年に出る見込みで、糖尿病性神経障害の痛みの治療におけるこの薬の可能性が明らかになります。したがって、上記のような要因から、予測期間中、市場は牽引役となることが期待されます。

痛みを伴う糖尿病性末梢神経障害に対する非オピオイド治療法の調査資金が増加し、市場成長を牽引する見込み

2022年に発表されたNIH HEAL Initiative Reportによると、NIHは糖尿病性神経障害性疼痛の非オピオイド治療法の開発に取り組む研究者を積極的に支援しています。これは、オピオイドをベースとした治療にしばしば伴う依存や中毒のリスクを軽減するために行われています。この目的のために、EPPIC-NETプログラムを通じて資金援助を受けているプロジェクトのひとつに、痛みを伴う糖尿病性末梢神経障害に対する新しい治療法の可能性を検証する第2相臨床試験があります。

この試験でテストされる分子は、前臨床試験ですでに大きな可能性を示しており、中毒や依存のリスクを伴わずに効果的な鎮痛をもたらす可能性があると考えられています。糖尿病性神経障害性疼痛に苦しむ患者にとって、この新しい治療法が画期的なものになることが期待されます。糖尿病性神経障害性疼痛は、多くの場合、副作用を伴うオピオイドベースの治療法に頼らざるを得ないです。

これに加えて、NIH HEAL Initiativeは、薬物の使用や慢性疼痛の発症に個人の環境が果たす重要な役割を認識する研究にも資金を提供しています。疼痛管理に対してより総合的なアプローチをとることで、疼痛を緩和するだけでなく、その原因となる根本的な問題にも対処できるような治療法を開発したいと考えています。

したがって、NIH HEAL Initiativeの取り組みは、疼痛管理に革命をもたらし、慢性疼痛に苦しむ何百万もの人々の生活を改善するための重要な一歩です。したがって、上記のような要因から、予測期間中、市場は牽引役となることが期待されます。

糖尿病性神経障害治療の副作用が市場成長の妨げになる見込み

糖尿病性神経障害は、糖尿病患者の最大70％が罹患しており、通常は足、脚、腕、手に不快感、しびれ、灼熱感、しびれなどの症状を伴う。重篤な糖尿病性神経障害の管理は困難であり、治療の選択肢は限られています。米国神経学会は、症状を緩和する最も強力な薬として、プレガバリン、ガバペンチン、デュロキセチン、ベンラファキシンなどを推奨しています。

処方薬は、胃障害、心臓病、その他の副作用を引き起こす可能性のある非ステロイド性抗炎症薬などが唯一の選択肢であることが多いです。三環系抗うつ薬は、脳のノルエピネフリンとセロトニンレベルに作用する最も強力な疼痛関連抗うつ薬ですが、眠気、体重増加、口渇、ドライアイ、その他の副作用を引き起こす可能性があります。また、同様の薬は血圧や心拍数の問題、めまいを引き起こすこともあります。したがって、上記の要因のために、市場は予測期間中に低迷すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病性神経障害性疼痛の潜在的治療法
      • 糖尿病性神経障害性疼痛治療薬の臨床試験の増加
      • 痛みを伴う糖尿病性末梢神経障害に対する非オピオイド治療研究資金の増加
    • 抑制要因
      • 糖尿病性神経障害治療の副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • 特許分析
  • ロシア・ウクライナ紛争分析
  • DMIの見解

第6章 COVID-19分析

第7章 神経障害タイプ別

  • 末梢神経障害
  • 自律神経障害
  • 近位神経障害
  • 局所神経障害

第8章 薬剤クラス別

  • 抗うつ薬
    • 三環系抗うつ薬（TCAs）
      • アミトリプチリン
      • ノルトリプチリン
      • デシプラミン
      • イミプラミン
    • セロトニン・ノルエピネフリン再取り込み阻害薬（SNRIs）
      • デュロキセチン
      • ベンラファキシン
    • セロトニン再取り込み阻害薬（SSRI）
      • シタロプラム
      • パロキセチン
  • 抗けいれん薬
    • カルシウムα2δ系抗けいれん薬
      • ガバペンチン
      • プレガバリン
    • ナトリウムチャネル系抗けいれん薬
      • カルバマゼピン
      • トピラマート
  • 鎮痛薬
    • オピオイド鎮痛薬
      • モルヒネ
      • オキシコドン
      • タペンタドール
    • 局所鎮痛薬
      • カプサイシン
      • リドカイン

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Eli Lilly and Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Grunenthal
  • Collegium Pharmaceutical, Inc.
  • Lupin
  • Daiichi Sankyo
  • Azurity Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Endo International plc.（Par Pharmaceutical）
  • Johnson & Johnson（Janssen Pharmaceuticals）

第13章 付録

目次
Product Code: PH6779

Overview

Global Diabetic Neuropathic Pain Market reached US$ 1.8 billion in 2022 and is expected to reach US$ 2.8 billion by 2030, growing with a CAGR of 6.1% during the forecast period 2023-2030.

The development of novel treatments for diabetic neuropathy is a trend for the global diabetic neuropathic pain market. For instance, on July 27, 2023, Gujarat-based pharma company Asprius Lifesciences announced that it has developed treatment for diabetic neuropathy, a condition that results in nerve damage in peripheral areas of the body. The company said it has already filed a patent for the Fixed-Dose Combination (FDC) that holds promise in treating peripheral neuropathy, a prevalent condition affecting over 2 percent of the global population.

Nerve damage caused by diabetes leads to diabetic neuropathy, a condition that results from uncontrolled high blood sugar levels. Diabetic neuropathic pain is a chronic pain type that arises from this condition. This pain exhibits symptoms such as burning sensations, discomfort, numbness, tingling, and shooting or stabbing pain. Peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy are the different forms of diabetic neuropathic pain. The treatment options available for diabetic neuropathic pain include analgesics, antidepressants, anticonvulsants, and others.

Furthermore, the increasing clinical trials of drugs, increasing prevalence of peripheral neuropathy, and novel treatment for diabetic neuropathic pain are the factors expected to drive the market over the forecast period.

Dynamics

Potential Treatment for Diabetic Neuropathic Pain is Expected to Drive Market Growth

The article from the National Center for Biotechnology Information, published in 2022, has shed light on the effectiveness of lipoic acid as a potent antioxidant that could potentially improve nerve blood flow, reduce oxidative stress, and enhance distal nerve conduction in patients with diabetic neuropathy. This powerful antioxidant has been proposed as a promising treatment for diabetic neuropathic pain, owing to its ability to alleviate symptoms and improve the quality of life in patients suffering from painful diabetic neuropathy.

Furthermore, lipoic acid has been shown to increase the levels of reduced glutathione, which is an important endogenous antioxidant, and to help regulate blood sugar levels. In clinical trials, it was found that 600 mg of alpha-lipoic acid was effective in managing pain associated with diabetic neuropathy. However, further research is required to establish its efficacy and safety.

Therefore, the impact of lipoic acid on the market will ultimately depend on the successful translation of recent advancements into practical treatments for those suffering from diabetic neuropathic pain. Hence, owing to the above factors, the market is expected to drive the market over the forecast period.

Increasing Clinical Trials of Drugs for Diabetic Neuropathic Pain is Expected to Drive Market Growth

The EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA (EN21-01) is an ongoing clinical trial that aims to explore the potential of NRD135S in alleviating the symptoms of painful diabetic peripheral neuropathy (PDPN). As a double-blind Phase II study, it is designed to evaluate the pharmacokinetics/pharmacodynamics, safety, tolerability, and efficacy of NRD135S over 13 weeks.

Currently in development, NRD135S is a novel drug expected to provide a treatment option for PDPN. Researchers aim to compare its effects to a placebo pill without active ingredients to evaluate its safety and efficacy in treating diabetic neuropathy pain.

The clinical trial conducted by Novaremed Ltd. involves multiple locations in the United States and Europe. Participants will be randomly assigned to receive either NRD135S or a placebo pill, ensuring unbiased results. If found safe and effective, NRD135S could significantly impact those suffering from PDPN. Results are expected in 2023, revealing the drug's potential in treating diabetic neuropathy pain. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Rising Funds for Research in Non-Opioid Treatments for Painful Diabetic Peripheral Neuropathy is Expected to Drive Market Growth

The NIH HEAL Initiative Report published in 2022, states that the organization is actively supporting researchers who are working towards developing non-opioid treatments for diabetic neuropathic pain. This is being done to reduce the risk of dependence or addiction that is often associated with opioid-based treatments. To this end, one of the projects that have been funded through the EPPIC-NET program is a phase 2 clinical trial that will be testing a potential new treatment for painful diabetic peripheral neuropathy.

The molecule being tested in this trial has already shown great promise in preclinical studies and is believed to have the potential to provide effective pain relief without the risk of addiction or dependence. It is hoped that this new treatment will prove to be a game-changer for patients suffering from diabetic neuropathic pain, who often have to rely on opioid-based treatments that come with a host of negative side effects.

In addition to this, the NIH HEAL Initiative is also funding research that recognizes the crucial role that an individual's environment plays in drug use and the development of chronic pain. By taking a more holistic approach to pain management, the organization is hoping to develop treatments that not only alleviate pain but also address the underlying issues that contribute to it.

Therefore, the NIH HEAL Initiative's efforts are a significant step towards revolutionizing pain management and improving the lives of millions of people who suffer from chronic pain. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Side Effect of Diabetic Neuropathy Treatment is Expected to Hamper the Market Growth

Diabetic neuropathy affects up to 70% of diabetic people, usually in the feet, legs, arms, and hands, with symptoms like discomfort, tingling, burning, and numbness. Managing severe diabetic neuropathy can be challenging, with limited care options available. The American Academy of Neurology recommends pregabalin, gabapentin, duloxetine, venlafaxine, and other drugs as the most powerful medications to alleviate the symptoms.

Prescription medication is often the only option, such as NSAIDs, which can cause stomach trouble, heart disease, and other side effects. Tricyclic antidepressants are the most powerful pain-related antidepressants that affect the norepinephrine and serotonin levels of the brain, but they can cause drowsiness, weight gain, dry mouth, dry eyes, and other side effects. Similar drugs may also lead to blood pressure, heart rate issues, and dizziness. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

Segment Analysis

The global diabetic neuropathic pain market is segmented based on neuropathy type, drug class, distribution channel and region.

The Peripheral Neuropathy from the Neuropathy Type Segment Accounted for Approximately 41.5% of the Diabetic Neuropathic Pain Market Share

Diabetic Peripheral Neuropathy (DPN) is a nerve damage that can occur as a complication of diabetes mellitus. Diabetes mellitus is a chronic metabolic disorder characterized by high blood sugar levels. The peripheral nerves, which are responsible for transmitting information between the central nervous system (brain and spinal cord) and the rest of the body, including the limbs and organs, are specifically affected by DPN.

To treat peripheral neuropathy, antidepressants such as nortriptyline, desipramine, imipramine, and amitriptyline are used. Other types of antidepressants, such as duloxetine, venlafaxine, paroxetine, and citalopram, are also used. Additionally, anticonvulsants such as gabapentin and pregabalin are prescribed for the treatment of peripheral neuropathy. Sometimes skin creams, patches, or sprays such as lidocaine are also used.

The market segment growth of diabetic peripheral neuropathy is expected to be driven by factors such as the increasing prevalence of the condition, pharmacological advances in the management of diabetes-associated peripheral neuropathy, and increasing clinical trials of drugs over the forecast period.

For instance, according to ClinicalTrials.Gov., an early phase 1 randomized controlled trial sponsored by the China Academy of Chinese Medical Sciences and led by Zhong Wang is evaluating the effectiveness of Liuweiluobi Granule, a Chinese herbal medicine, in improving neurotransmission function in patients with diabetic peripheral neuropathy (DPN).

The study aims to assess whether Liuweiluobi Granule can effectively enhance neurotransmission function in patients with diabetic peripheral neuropathy. Preliminary animal experiments suggested that the granule's effects on protecting peripheral motor nerves and reducing inflammation. Additionally, the granule did not show toxicity at a certain concentration.

Therefore, the results will provide valuable insights into the potential benefits of using Liuweiluobi Granule as a treatment for diabetic peripheral neuropathy.

Further, researchers at Loma Linda University Health have discovered a new treatment for diabetic peripheral neuropathy (DPN) called Intraneural Facilitation (INF). INF treatment is effective in reducing pain caused by DPN by restoring blood flow to damaged nerves. The previous treatment for DPN included glycemic control, foot care, pain management, and medication utilization as recommended by the American Diabetes Association.

However, the benefits of pharmacology have only shown modest results in slowing the progression of the disease and reducing pain associated with DPN. INF treatment involves three holds or positions that widen tiny openings in arteries surrounding nerves, improving blood flow to targeted nerves. Improved blood flow stimulates healing and reduces or stops nerve pain. One of the lead researchers, Mark Bussell, DPT, who developed INF treatment, hypothesized that INF would decrease perceived pain, and improve balance, ambulation, quality of life, and protective sensory function in patients with moderate-to-severe DPN.

This study enrolled patients with Type 2 diabetes mellitus and moderate-to-severe DPN symptoms below the ankle for a single-blind, randomized clinical trial. Patients were randomly assigned to receive either INF or sham treatment. INF physical therapists provided therapy for 50 to 60 minutes, three times a week for three weeks, while the sham treatment group was led to believe they received therapy for three weeks. Quality of life, balance, gait, protective sensory function, and pain outcome measures were compared between the two groups using pre- and post-treatment data. The INF group showed post-treatment improvements in protective sensory function and composite static balance score, and INF treatment improved pain perception.

Therefore, INF treatment is effective in reducing pain caused by diabetic peripheral neuropathy (DPN) by restoring blood flow to damaged nerves. The treatment also improves pain perception, protective sensory function, and composite static balance score in patients with moderate-to-severe DPN. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.7% of the Market Share in 2022, Owing to the Rising Investments in the Treatment of Diabetic Neuropathy, Increasing Prevalence of Peripheral Neuropathy, and Increasing Clinical Trials for Drugs

North America region is expected to hold the largest market share over the forecast period owing to the rising investments for the treatment of diabetic neuropathy, increasing prevalence of peripheral neuropathy, and increasing clinical trials for drugs.

For instance, in 2022, EPPIC-Net is a consortium funded by the National Institutes of Health's Helping to End Addiction Long-term (HEAL) initiative to accelerate the development of non-addictive pain therapies by supporting early-phase clinical trials of promising agents. Drs. Robinson-Papp and George led a team to create the platform protocol for this trial, a novel approach that includes multiple subgroups and substudies and enables the evaluation of more than one investigational agent. The platform protocol creates a standardized, rigorous process for assessing pharmaceutical agents that could accelerate time to market.

Additionally, on November 16, 2020, a $3 million NIH grant was awarded to a team of U.S./Canadian investigators, including researchers from the EVMS Strelitz Diabetes Center, to study a potentially groundbreaking treatment for diabetic neuropathy. In collaboration with the University of California San Diego and Canadian drug development company WinSanTor, the EVMS scientists secured the NIH-NIDDK Small Business Innovation Research (SBIR) grant. The EVMS team has been granted approximately $1 million to conduct a phase 2 clinical study of the medication Pirenzepine for neuropathy. EVMS is the only site in the U.S. researching this medication for neuropathy. Hence, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the diabetic neuropathic pain market include: Eli Lilly and Company, Grunenthal, Collegium Pharmaceutical, Inc., Lupin, Daiichi Sankyo, Azurity Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., Endo International plc. (Par Pharmaceutical) and Johnson & Johnson (Janssen Pharmaceuticals) among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the market for Diabetic Neuropathic Pain (DNP) treatments and various aspects of healthcare. Healthcare services, including elective procedures and non-urgent medical appointments, were disrupted, leading to delays in diagnosis, treatment adjustments, and follow-up care for DNP patients. Clinical trials and research activities related to DNP treatments were also put on hold due to lockdowns, restrictions, and reprioritization of resources toward COVID-19 research, which could affect the introduction of new therapies or the advancement of existing ones.

The COVID-19 pandemic overwhelmed hospitals and healthcare facilities with cases, leading to a diversion of resources, personnel, and attention away from other medical conditions such as DNP. This strain on the healthcare system could have affected timely access to care for DNP patients. Telehealth services were rapidly adopted as in-person visits became less feasible. While this allowed some DNP patients to receive consultations and follow-up care remotely, it might not have been as effective for certain diagnostic and treatment procedures.

Diabetic patients, including those with DNP, were considered at higher risk for severe COVID-19 complications, leading to increased precautions and avoidance of healthcare settings, potentially impacting disease management. Medical conferences and educational events were moved to virtual platforms, impacting the dissemination of new research, treatment guidelines, and information about DNP management.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has the potential effect on the healthcare sector and the market for Diabetic Neuropathic Pain (DNP) treatments. In areas affected by conflict, healthcare resources, and infrastructure could be redirected to emergency services and treating war-related injuries, potentially reducing the focus on chronic conditions like DNP and limiting the availability of specialized care. Additionally, research and development activities related to DNP treatments could be hampered in regions directly affected by the conflict, as institutions and researchers shift their focus to more immediate concerns, delaying advancements in DNP therapies.

By Neuropathy Type

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

By Drug Class

  • Antidepressants

Tricyclic Antidepressants (TCAs)

  • Amitriptyline
  • Nortriptyline
  • Desipramine
  • Imipramine

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

  • Duloxetine
  • Venlafaxine

Serotonin Reuptake Inhibitors (SSRIs)

  • Citalopram
  • Paroxetine
  • Anticonvulsants

Calcium alpha-2-delta anticonvulsants

  • Gabapentin
  • Pregabalin

Sodium channel anticonvulsants

  • Carbamazepine
  • Topiramate
  • Analgesics

Opioid Analgesics

  • Morphine
  • Oxycodone
  • Tapentadol

Topical Analgesics

  • Capsaicin
  • Lidocaine

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On July 22, 2022, Vertex Pharmaceuticals Incorporated announced that following the positive Phase 2 results earlier this year and having reached an agreement on the design of the pivotal development program with the U.S. Food and Drug Administration (FDA), Vertex plans to advance the selective NaV1.8 inhibitor VX-548 into Phase 3 clinical trials in the fourth quarter of 2022. Vertex also intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by the end of this year. In addition, the FDA has granted VX-548 Breakthrough Therapy Designation for the treatment of moderate-to-severe acute pain.

Why Purchase the Report?

  • To visualize the global diabetic neuropathic pain market segmentation based on neuropathy type, drug class, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of diabetic neuropathic pain market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

DataM Intelligence Opinion:

According to the DataM Intelligence, the management of Diabetic Neuropathic Pain (DNP) is a complex issue that requires addressing various factors. While promising treatment options, clinical trials, and research funding provide hope for better outcomes, the healthcare sector has faced challenges due to geopolitical events and disruptions like COVID-19. All stakeholders need to stay informed and engaged to make the most of new opportunities and overcome obstacles.

The market for treating Diabetic Neuropathic Pain (DNP) has the potential for growth through innovative approaches. Studies have shown lipoic acid's antioxidative effects, while ongoing clinical trials explore non-opioid options, such as NRD135S. The Intraneural Facilitation (INF) treatment has shown promise in enhancing blood flow and reducing pain. However, current treatment side effects and geopolitical events, such as conflicts and the COVID-19 pandemic, pose challenges. Meeting the evolving needs of DNP patients requires adaptable healthcare systems that balance advancements and challenges.

The global diabetic neuropathic pain market report would provide approximately 61 tables, 59 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Neuropathy Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Potential Treatment for Diabetic Neuropathic Pain
      • 4.1.1.2. Increasing Clinical Trials of Drugs for Diabetic Neuropathic Pain
      • 4.1.1.3. Rising Funds for Research in Non-Opioid Treatments for Painful Diabetic Peripheral Neuropathy
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effect of Diabetic Neuropathy Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Patent Analysis
  • 5.7. Russian-Ukraine Conflict Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Neuropathy Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Neuropathy Type
    • 7.1.2. Market Attractiveness Index, By Neuropathy Type
  • 7.2. Peripheral Neuropathy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Autonomic Neuropathy
  • 7.4. Proximal Neuropathy
  • 7.5. Focal Neuropathy

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Antidepressants*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Tricyclic Antidepressants (TCAs)
      • 8.2.3.1. Amitriptyline
      • 8.2.3.2. Nortriptyline
      • 8.2.3.3. Desipramine
      • 8.2.3.4. Imipramine
    • 8.2.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
      • 8.2.4.1. Duloxetine
      • 8.2.4.2. Venlafaxine
    • 8.2.5. Serotonin Reuptake Inhibitors (SSRIs)
      • 8.2.5.1. Citalopram
      • 8.2.5.2. Paroxetine
  • 8.3. Anticonvulsants
    • 8.3.1. Calcium alpha-2-delta anticonvulsants
      • 8.3.1.1. Gabapentin
      • 8.3.1.2. Pregabalin
    • 8.3.2. Sodium channel anticonvulsants
      • 8.3.2.1. Carbamazepine
      • 8.3.2.2. Topiramate
  • 8.4. Analgesics
    • 8.4.1. Opioid Analgesics
      • 8.4.1.1. Morphine
      • 8.4.1.2. Oxycodone
      • 8.4.1.3. Tapentadol
    • 8.4.2. Topical Analgesics
      • 8.4.2.1. Capsaicin
      • 8.4.2.2. Lidocaine

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Neuropathy Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Neuropathy Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Neuropathy Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Neuropathy Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Neuropathy Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Eli Lilly and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Grunenthal
  • 12.3. Collegium Pharmaceutical, Inc.
  • 12.4. Lupin
  • 12.5. Daiichi Sankyo
  • 12.6. Azurity Pharmaceuticals, Inc.
  • 12.7. Novartis AG
  • 12.8. Pfizer, Inc.
  • 12.9. Endo International plc. (Par Pharmaceutical)
  • 12.10. Johnson & Johnson (Janssen Pharmaceuticals)

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us